This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy Manufacturing & Commercialization US
September 23-26, 2024
Hynes Convention CenterBoston, MA

Nathan Lee
Senior Director, Gene Therapy CMC at Poseida Therapeutics


"Nathan is currently Senior Director of CMC at Poseida Therapeutics. At Poseida, he leads all aspects of the CMC product development lifecycle for Poseida’s gene therapy programs. He has 15+ years of experience specializing in development, manufacturing, and CMC strategy leadership. He has experience ranging from early development through to commercial lifecycle support. Nathan has worked with numerous therapeutic modalities including large molecules (Fc fusion, enzymes, monoclonal antibodies), viral vector (AAV) and nonviral (mRNA/sgRNA/LNP, in vivo and ex vivo) gene therapies. Nathan has an ME in Chemical Engineering from Tufts University and a BS in Biochemistry from the University of New Hampshire."

Agenda Sessions

  • Strategic CMC considerations, challenges and opportunities for nonviral gene therapies